Genentech, Inc.

F. Hoffmann-la Roche Ag

Lin, Kui

Punnoose, Elizabeth

Seshagiri, Somasekar

Elizabeth Punnoose

Deepak Sampath

Kui Lin

Michelle Nannini

Jeffrey Wallin

Premal Patel

Jo-Anne Hongo

Bonnee Rubinfeld

Somasekar Seshagiri

Rajesh Vij

Mark Lackner

Brian Lee

Siminder Atwal

The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R, R, R, R, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use

The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer. 

Combinations of AKT and MEK inhibitor compounds, and methods of use

The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.

Compositions and methods for prostate cancer analysis

Growing community of inventors

South San Francisco, CA, United States of America

Elizabeth Punnoose